menu
    • menu
    [{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Terragenx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Iodine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Novo Integrated Sciences \/ Novo Integrated Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Novo Integrated Sciences \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Sarfez Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Torsemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Integrated Sciences \/ Novo Integrated Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Novo Integrated Sciences \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iodine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Novo Integrated Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Integrated Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Novo Integrated Sciences

    Menu

    Novo Integrated Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iodine

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s ...

                            Details : IoNovo for Kids pure iodine oral spray has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey.

                            Brand Name : IoNovo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 13, 2023

                            Lead Product(s) : Iodine

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Sarfez Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Ph...

                            Details : Sarfez’s FDA-approved, once-a-day novel formulation of loop diuretic torsemide, SOAANZ®, provides a new treatment option for patients suffering from heart failure who experience persistent edema or swelling in the lower limbs and/or abdomen.

                            Brand Name : Soaanz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 30, 2022

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Sarfez Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Novo Integrated Sciences

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Terragenx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Can...

                            Details : Novo has acquired the intellectual property for iodine in an aqueous form that can be safely ingested and has been proven to kill viruses, bacteria and protozoa when sprayed onto your mucous membranes, the entry points for various airborne viruses.

                            Brand Name : Iodine

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 30, 2021

                            Lead Product(s) : Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Terragenx

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth